Healthcare

HB 218 revises the practice of optometry by expanding the scope of services licensed optometrists can provide. It permits optometrists to perform certain in-office surgical procedures and laser surgical procedures, specifically limited to the anterior segment of the eye and adnexa. However, the bill explicitly excludes penetrating intraocular surgery, intravitreal injection, and refractive surgery. To perform laser surgical procedures, optometrists must be certified by the board after completing required didactic and clinical training. This act takes effect on July 1, 2025.

This bill makes Montana's community health aide program permanent by removing its previously scheduled expiration date. It directs the Department of Public Health and Human Services to apply for Medicaid coverage for services provided by certified community health aides. The change directly affects community health aides and their patients, particularly in rural and tribal communities, ensuring continued access to essential healthcare services without future legislative renewal.

This resolution urges Congress to amend the federal Radiation Exposure Compensation Act (RECA) to include Montanans affected by historical nuclear testing. It specifically highlights that 15 Montana counties (including Meagher, Jefferson, and Gallatin) were heavily exposed during U.S. nuclear tests from 1945-1962, as confirmed by a 1997 government study, yet Montanans remain excluded from RECA compensation. The resolution does not create new policy but formally requests Congress to revise RECA to cover these individuals, who may suffer radiation-related illnesses without access to federal aid. It is a procedural resolution, not a bill, and directs Montana’s Secretary of State to send copies to U.S. lawmakers.

HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.